First Light Asset Management LLC Has $54.30 Million Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

First Light Asset Management LLC decreased its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 5.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,023,256 shares of the company's stock after selling 167,389 shares during the quarter. Amylyx Pharmaceuticals comprises 3.3% of First Light Asset Management LLC's holdings, making the stock its 10th largest holding. First Light Asset Management LLC owned 2.71% of Amylyx Pharmaceuticals worth $54,298,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Integrated Wealth Concepts LLC bought a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at about $157,000. Arizona State Retirement System raised its stake in shares of Amylyx Pharmaceuticals by 9.5% in the second quarter. Arizona State Retirement System now owns 19,825 shares of the company's stock worth $356,000 after purchasing an additional 1,726 shares during the last quarter. Corient Private Wealth LP purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $1,065,000. California State Teachers Retirement System lifted its holdings in shares of Amylyx Pharmaceuticals by 2,106.9% in the second quarter. California State Teachers Retirement System now owns 1,434,501 shares of the company's stock valued at $25,764,000 after purchasing an additional 1,369,499 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at approximately $18,912,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX opened at $32.40 on Thursday. The firm has a fifty day moving average of $25.15 and a 200 day moving average of $18.62. Amylyx Pharmaceuticals, Inc. has a 52-week low of $10.83 and a 52-week high of $41.14. The firm has a market capitalization of $3.61 billion, a PE ratio of -22.66 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). On average, sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Insider Transactions at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the business's stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMLX. Guggenheim raised their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a "buy" rating in a research report on Thursday, August 27th. Citigroup boosted their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a "buy" rating in a report on Monday, August 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Robert W. Baird lifted their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research note on Wednesday, August 19th. Finally, Wolfe Research raised Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $36.50.

Amylyx Pharmaceuticals Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.